[go: up one dir, main page]

WO2008144690A3 - Compositions et procédés d'amélioration de l'absorption d'agents actifs - Google Patents

Compositions et procédés d'amélioration de l'absorption d'agents actifs Download PDF

Info

Publication number
WO2008144690A3
WO2008144690A3 PCT/US2008/064233 US2008064233W WO2008144690A3 WO 2008144690 A3 WO2008144690 A3 WO 2008144690A3 US 2008064233 W US2008064233 W US 2008064233W WO 2008144690 A3 WO2008144690 A3 WO 2008144690A3
Authority
WO
WIPO (PCT)
Prior art keywords
compositions
methods
active agent
agent absorption
enhancing active
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2008/064233
Other languages
English (en)
Other versions
WO2008144690A2 (fr
Inventor
Chung Shih
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
NexusPharma Inc
Original Assignee
NexusPharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US11/805,202 external-priority patent/US8426466B2/en
Application filed by NexusPharma Inc filed Critical NexusPharma Inc
Priority to EP08755962.1A priority Critical patent/EP2150243A4/fr
Publication of WO2008144690A2 publication Critical patent/WO2008144690A2/fr
Publication of WO2008144690A3 publication Critical patent/WO2008144690A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0031—Rectum, anus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

L'invention concerne des compositions et procédés d'amélioration de l'absorption d'agents actifs à travers la muqueuse de sujets animaux. Des compositions ayant des liaisons biodégradables sont incluses, conférant une diminution de probabilité de toxicité. L'invention concerne également des procédés d'utilisation et des formes galéniques appropriées.
PCT/US2008/064233 2007-05-21 2008-05-20 Compositions et procédés d'amélioration de l'absorption d'agents actifs Ceased WO2008144690A2 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP08755962.1A EP2150243A4 (fr) 2007-05-21 2008-05-20 Compositions et procédés d'amélioration de l'absorption d'agents actifs

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US11/805,202 2007-05-21
US11/805,202 US8426466B2 (en) 2006-05-22 2007-05-21 Compositions and methods for enhancing active agent absorption
US409907P 2007-11-21 2007-11-21
US61/004,099 2007-11-21

Publications (2)

Publication Number Publication Date
WO2008144690A2 WO2008144690A2 (fr) 2008-11-27
WO2008144690A3 true WO2008144690A3 (fr) 2009-02-26

Family

ID=40122287

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2008/064233 Ceased WO2008144690A2 (fr) 2007-05-21 2008-05-20 Compositions et procédés d'amélioration de l'absorption d'agents actifs

Country Status (2)

Country Link
EP (1) EP2150243A4 (fr)
WO (1) WO2008144690A2 (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104906592B (zh) * 2011-02-25 2017-11-03 广州南沙龙沙有限公司 用于蛋白质药物偶联物的支链联接体
EP3031905A4 (fr) * 2013-08-07 2017-04-26 Kyoto University Méthode de production de cellule productrice d'hormone pancréatique

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5817624A (en) * 1995-06-05 1998-10-06 Alza Corporation Permeation enhancer compositions for increased absorption of therapeutic proteins through the colonic membrane
WO2001054514A1 (fr) * 2000-01-27 2001-08-02 Aqua Solution Inc. Composition pour administration intestinale
WO2003057170A2 (fr) * 2002-01-07 2003-07-17 Emisphere Technologies, Inc. Insulinotherapie par voie orale
CN1857727A (zh) * 2006-03-13 2006-11-08 新疆维吾尔自治区畜牧科学院兽医研究所 动物皮肤渗透剂

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5773647A (en) 1997-02-07 1998-06-30 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5817624A (en) * 1995-06-05 1998-10-06 Alza Corporation Permeation enhancer compositions for increased absorption of therapeutic proteins through the colonic membrane
WO2001054514A1 (fr) * 2000-01-27 2001-08-02 Aqua Solution Inc. Composition pour administration intestinale
WO2003057170A2 (fr) * 2002-01-07 2003-07-17 Emisphere Technologies, Inc. Insulinotherapie par voie orale
CN1857727A (zh) * 2006-03-13 2006-11-08 新疆维吾尔自治区畜牧科学院兽医研究所 动物皮肤渗透剂

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
MENG, B. ET AL.: "Hypoglycemic effect of insulin W/O microemulsions following intestinal administration to rats.", ZHONGGUO YAOKE DAXUE XUEBAO., vol. 37, no. 4, 2006, pages 304 - 307, ISSN: 1000-5048 *
See also references of EP2150243A4 *

Also Published As

Publication number Publication date
EP2150243A4 (fr) 2013-08-21
WO2008144690A2 (fr) 2008-11-27
EP2150243A2 (fr) 2010-02-10

Similar Documents

Publication Publication Date Title
BRPI0806531A2 (pt) Composto, composição farmacêutica, agente terapêutico, e, uso do composto.
WO2007077561A3 (fr) Compositions et procédés permettant d'améliorer le captage in-vivo d'agents pharmaceutiques
ZA200807767B (en) Nitrogenated heterocyclic derivative, and pharmaceutical agent comprising the derivative as active ingredient
CL2007002017A1 (es) Compuestos derivados de [4,5']-bipirimidinil-6,4'-diamina; composicion farmaceutica; y uso como inhibidor de la actividad de cinasa en cancer de vejiga, cancer cervical y mieloma multiple.
CL2007002513A1 (es) Compuestos derivados de isoindolina sustituidos, compuestos intermediarios; composicion farmaceutica; y uso en el tratamiento y prevencion de enfermedades tales como cancer, dolor, degeneracion macular, entre otras.
CR8642A (es) Compuestos, composiciones farmaceuticas y metodos para su uso en el tratameinto de desordenes metabolicos
WO2007127333A3 (fr) Compositions pour le traitement et la prévention du gonflement des paupières
IL196108A0 (en) Active agent formulations, methods of making, and methods of use
WO2006042146A3 (fr) Conjugues mutifonctionnels de nanoparticules et utilisation de ceux-ci
WO2007087068A3 (fr) Inhibiteurs de tyrosine kinase et leurs utilisations
EP2476461A3 (fr) Formulations pour le traitement du cancer
IL184051A (en) Acetylated GLP-1 compounds, containing and using pharmaceutical preparations
BRPI0718688A2 (pt) Composições de baixa irritação e métodos para preparar as mesmas.
WO2005069865A3 (fr) Derives de pyrrolopyrimidine et analogues et utilisation dans le traitement et la prevention de maladies
TW200745124A (en) Azepinoindole derivatives as pharmaceutical agents
CL2007002920A1 (es) Compuestos derivados de 2-aminocarbonilpiridina; composicion farmaceutica; y uso para el tratamiento de trastornos vasculares oclusivos.
WO2009061431A3 (fr) Compositions pour le traitement et la prévention du gonflement des paupières
WO2009071689A3 (fr) Dérivés d'oxindole substitués par halogène en position 5 et leur utilisation pour traiter des maladies liées à la vasopressine
CL2007003038A1 (es) Compuestos derivados de 2-fenil-6-aminocarbonil-pirimidina; composicion farmaceutica; y uso en el tratamiento de trastornos vasculares oclusivos.
SI1909843T1 (sl) Protitumorski biokonjugati hialuronske kisline ali njenih derivatov, dobljeni z indirektno kemijsko konjugacijo, in njihova uporaba na farmacevtskem področju
MX2007010560A (es) Roflumilast para el tratamiento de diabetes mellitus.
CY1117174T1 (el) ΧΡΗΣΗ 24-norUDCA ΓΙΑ ΤΗΝ ΑΓΩΓΗ ΧΟΛΟΣΤΑΤΙΚΩΝ ΝΟΣΗΜΑΤΩΝ ΤΟΥ ΗΠΑΤΟΣ
WO2009156182A3 (fr) Dérivés de l'uracile et leur utilisation
PT2056805E (pt) Utilização de derivados de 2,5-di-hidroxibenzeno para o tratamento de reacção tecidular
WO2010074936A3 (fr) Enzastaurine dans le traitement du cancer

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08755962

Country of ref document: EP

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: 2008755962

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: DE